<p>随着亚洲市场在强劲的企业盈利和韧性的经济指标的推动下经历增长期，投资者越来越关注那些内部持股比例较高的公司。在这种环境下，结合高内部持股和显著预期盈利增长的股票，对于那些希望与对公司成功有切身利益的内部人士利益一致的投资者来说，可能会呈现出诱人的机会。</p>
<h3>亚洲内部持股比例高的十大成长公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>Techwing (KOSDAQ:A089030)</td>
<td>19.1%</td>
<td>68%</td>
</tr>
<tr>
<td>苏州三门科技 (SZSE:300522)</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Sineng ElectricLtd (SZSE:300827)</td>
<td>36%</td>
<td>25.8%</td>
</tr>
<tr>
<td>上海华测导航科技 (SZSE:300627)</td>
<td>24.3%</td>
<td>24.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 Technology (TPEX:6643)</td>
<td>30.8%</td>
<td>95.5%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>43%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>32.8%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>12.8%</td>
<td>43.7%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们快速增长的亚洲内部持股高的公司筛选器中的 593 只股票的完整列表。</p>
<p>让我们探索筛选结果中的几个突出选项。</p>
<h2>荣昌生物 (SEHK:9995)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 荣昌生物有限公司是一家生物制药公司，专注于在中国大陆和美国发现、开发和商业化用于自身免疫、肿瘤和眼科疾病的生物制剂，市值约为港币 401.4 亿。</p>
<p><strong>运营：</strong> 荣昌生物的生物制药研究、服务、生产和销售收入约为人民币 19.1 亿元。</p>
<p><strong>内部持股：</strong> 11.2%</p>
<p><strong>盈利增长预测：</strong> 每年 66.3%。</p>
<p>荣昌生物正在经历显著增长，预计盈利每年增长 66.34%，收入预计每年增长 24.6%，超过香港市场。尽管股价波动较大，但其交易价格显著低于估计的公允价值。最近的发展包括 RC148 在美国的临床试验获得 FDA 批准，以及 Telitacicept 的全球三期试验，突显其创新药物管线和未来在国际市场扩展的潜力。</p>
<ul>
<li>解锁我们对荣昌生物股票分析的全面见解，详见本增长报告。</li>
<li>我们的全面估值报告提出荣昌生物的股价可能高于其财务状况所能合理支持的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:9995 截至 2025 年 8 月的盈利和收入增长</p>
<h2>安徽壹石通材料科技有限公司 (SHSE:688733)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 安徽壹石通材料科技有限公司专注于锂电池涂层、电子通信功能填充和低烟卤素-free 阻燃材料，市值为人民币 52.4 亿元。</p>
<p><strong>运营：</strong> 该公司从其特种化学品部门产生的收入为人民币 5.1072 亿元。</p>
<p><strong>内部持股：</strong> 32.8%</p>
<p><strong>盈利增长预测：</strong> 每年 60.8%。</p>
<p>安徽壹石通材料科技有限公司预计将实现强劲扩张，预计盈利每年增长 60.8%，收入预计每年增长 23.7%，超过中国市场的增长率。该公司最近实现盈利，但面临大型一次性项目对其财务结果的影响。尽管存在这些挑战，最近几个月没有报告重大内部交易活动，表明内部人士对公司前景的情绪稳定。</p>
<ul>
<li>点击这里发现安徽壹石通材料科技有限公司的细微差别，查看我们的详细分析未来增长报告。</li>
<li>我们的估值报告揭示安徽壹石通材料科技有限公司的股票可能以溢价交易。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown"/></p>
<p>SHSE:688733 截至 2025 年 8 月的持股结构</p>
<h2>Caliway Biopharmaceuticals (TWSE:6919)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Caliway Biopharmaceuticals 有限公司及其子公司专注于开发用于美学医学和慢性炎症的药物，市值为新台币 2086.1 亿元。</p>
<p><strong>运营：</strong> Caliway Biopharmaceuticals 有限公司通过专注于美学医学和慢性炎症的药物开发产生收入。</p>
<p><strong>内部持股：</strong> 24.2%</p>
<p><strong>盈利增长预测：</strong> 每年 93.8%。</p>
<p>Caliway Biopharmaceuticals 正经历显著的增长潜力，预计收入每年增长 89%，超过台湾市场。该公司最近因被纳入 MSCI 全球标准指数而获得认可，并已启动其创新药物 CBL-514 的关键三期试验。尽管股价波动较大且当前缺乏有意义的收入，Caliway 在临床开发中的战略进展使其在未来三年内实现盈利的前景良好。</p>
<ul>
<li>点击这里深入了解 Caliway Biopharmaceuticals 的完整分析未来增长报告。</li>
<li>我们编制的估值报告表明 Caliway Biopharmaceuticals 当前的价格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth"/></p>
<p>TWSE:6919 截至 2025 年 8 月的盈利和收入增长</p>
<h2>关键要点</h2>
<ul>
<li>通过使用我们的筛选器，深入了解所有 593 家快速增长的亚洲内部持股高的公司。</li>
<li>对其他选项感到好奇？特朗普承诺将&#34;释放&#34;美国的石油和天然气，这 22 只美国股票的发展有望受益。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具如公司和/或信托实体间接持有的股票。所有引用的预测收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

壹石通

荣昌生物

<p>随着亚洲市场的增长，投资者正关注那些内部持股比例高且盈利增长显著的公司。值得注意的公司包括 Vuno（15.6% 的内部持股，109.8% 的盈利增长）、Techwing（19.1%，68%）和荣昌生物（11.2%，66.3%）。荣昌生物是一家生物制药公司，正在通过 FDA 试验和强劲的收入预测进行扩张。安徽壹石通材料科技（32.8%，60.8%）和 Caliway 生物制药（24.2%，93.8%）也展现出良好的增长潜力。分析强调了亚洲成长股中内部持股的投资机会，突出了投资者与公司内部人士之间利益的一致性</p>

<p>As Asian markets experience a period of growth, bolstered by strong corporate earnings and resilient economic indicators, investors are increasingly focusing on companies with robust insider ownership. In this environment, stocks that combine high insider stakes with significant expected earnings growth can present compelling opportunities for those seeking to align their interests with company insiders who have a vested interest in the firm's success.</p>
<div class="lb-trans"><p>随着亚洲市场在强劲的企业盈利和韧性的经济指标的推动下经历增长期，投资者越来越关注那些内部持股比例较高的公司。在这种环境下，结合高内部持股和显著预期盈利增长的股票，对于那些希望与对公司成功有切身利益的内部人士利益一致的投资者来说，可能会呈现出诱人的机会。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3>
<div class="lb-trans"><h3>亚洲内部持股比例高的十大成长公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>Techwing (KOSDAQ:A089030)</td>
<td>19.1%</td>
<td>68%</td>
</tr>
<tr>
<td>Suzhou Sunmun Technology (SZSE:300522)</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Sineng ElectricLtd (SZSE:300827)</td>
<td>36%</td>
<td>25.8%</td>
</tr>
<tr>
<td>Shanghai Huace Navigation Technology (SZSE:300627)</td>
<td>24.3%</td>
<td>24.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 Technology (TPEX:6643)</td>
<td>30.8%</td>
<td>95.5%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>43%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>32.8%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>12.8%</td>
<td>43.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部持股</strong></td>
<td><strong>盈利增长</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>109.8%</td>
</tr>
<tr>
<td>Techwing (KOSDAQ:A089030)</td>
<td>19.1%</td>
<td>68%</td>
</tr>
<tr>
<td>苏州三门科技 (SZSE:300522)</td>
<td>35.4%</td>
<td>77.7%</td>
</tr>
<tr>
<td>Sineng ElectricLtd (SZSE:300827)</td>
<td>36%</td>
<td>25.8%</td>
</tr>
<tr>
<td>上海华测导航科技 (SZSE:300627)</td>
<td>24.3%</td>
<td>24.3%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>28.2%</td>
</tr>
<tr>
<td>M31 Technology (TPEX:6643)</td>
<td>30.8%</td>
<td>95.5%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>43%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>32.8%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>12.8%</td>
<td>43.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 593 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们快速增长的亚洲内部持股高的公司筛选器中的 593 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>让我们探索筛选结果中的几个突出选项。</p>
</div><h2>RemeGen (SEHK:9995)</h2>
<div class="lb-trans"><h2>荣昌生物 (SEHK:9995)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of approximately HK$40.14 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 荣昌生物有限公司是一家生物制药公司，专注于在中国大陆和美国发现、开发和商业化用于自身免疫、肿瘤和眼科疾病的生物制剂，市值约为港币 401.4 亿。</p>
</div><p><strong>Operations:</strong> RemeGen's revenue from biopharmaceutical research, service, production, and sales amounts to approximately CN¥1.91 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 荣昌生物的生物制药研究、服务、生产和销售收入约为人民币 19.1 亿元。</p>
</div><p><strong>Insider Ownership:</strong> 11.2%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 11.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 66.3% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 66.3%。</p>
</div><p>RemeGen is experiencing significant growth, with earnings forecasted to grow 66.34% annually and revenue expected to increase by 24.6% per year, outpacing the Hong Kong market. Despite high share price volatility, it trades at a notable discount below its estimated fair value. Recent developments include FDA clearance for clinical trials of RC148 in the US and a global Phase 3 trial for Telitacicept, highlighting its innovative drug pipeline and potential for future expansion in international markets.</p>
<div class="lb-trans"><p>荣昌生物正在经历显著增长，预计盈利每年增长 66.34%，收入预计每年增长 24.6%，超过香港市场。尽管股价波动较大，但其交易价格显著低于估计的公允价值。最近的发展包括 RC148 在美国的临床试验获得 FDA 批准，以及 Telitacicept 的全球三期试验，突显其创新药物管线和未来在国际市场扩展的潜力。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of RemeGen stock in this growth report.</li>
<li>Our comprehensive valuation report raises the possibility that RemeGen is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对荣昌生物股票分析的全面见解，详见本增长报告。</li>
<li>我们的全面估值报告提出荣昌生物的股价可能高于其财务状况所能合理支持的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:9995 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>SEHK:9995 截至 2025 年 8 月的盈利和收入增长</p>
</div><h2>Anhui Estone Materials TechnologyLtd (SHSE:688733)</h2>
<div class="lb-trans"><h2>安徽壹石通材料科技有限公司 (SHSE:688733)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Anhui Estone Materials Technology Co., Ltd specializes in lithium battery coating, electronic communication functional filling, and low-smoke halogen-free flame-retardant materials in China with a market cap of CN¥5.24 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 安徽壹石通材料科技有限公司专注于锂电池涂层、电子通信功能填充和低烟卤素-free 阻燃材料，市值为人民币 52.4 亿元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥510.72 million from its specialty chemicals segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其特种化学品部门产生的收入为人民币 5.1072 亿元。</p>
</div><p><strong>Insider Ownership:</strong> 32.8%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 32.8%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 60.8% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 60.8%。</p>
</div><p>Anhui Estone Materials Technology Ltd. is projected to see robust expansion, with earnings anticipated to grow 60.8% annually and revenue expected to rise by 23.7% per year, surpassing the Chinese market's growth rates. The company recently turned profitable but faces challenges from large one-off items affecting its financial results. Despite these hurdles, no substantial insider trading activity has been reported in recent months, indicating stability in insider sentiment toward the company's prospects.</p>
<div class="lb-trans"><p>安徽壹石通材料科技有限公司预计将实现强劲扩张，预计盈利每年增长 60.8%，收入预计每年增长 23.7%，超过中国市场的增长率。该公司最近实现盈利，但面临大型一次性项目对其财务结果的影响。尽管存在这些挑战，最近几个月没有报告重大内部交易活动，表明内部人士对公司前景的情绪稳定。</p>
</div><ul>
<li>Click here to discover the nuances of Anhui Estone Materials TechnologyLtd with our detailed analytical future growth report.</li>
<li>Our valuation report unveils the possibility Anhui Estone Materials TechnologyLtd's shares may be trading at a premium.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里发现安徽壹石通材料科技有限公司的细微差别，查看我们的详细分析未来增长报告。</li>
<li>我们的估值报告揭示安徽壹石通材料科技有限公司的股票可能以溢价交易。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/87d4bd03-6a8a-4073-9576-545895fcbe5f/chart/ownership-breakdown"/></p>
<p>SHSE:688733 Ownership Breakdown as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:688733 截至 2025 年 8 月的持股结构</p>
</div><h2>Caliway Biopharmaceuticals (TWSE:6919)</h2>
<div class="lb-trans"><h2>Caliway Biopharmaceuticals (TWSE:6919)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries focus on developing drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$208.61 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Caliway Biopharmaceuticals 有限公司及其子公司专注于开发用于美学医学和慢性炎症的药物，市值为新台币 2086.1 亿元。</p>
</div><p><strong>Operations:</strong> Caliway Biopharmaceuticals Co., Ltd. generates revenue through its focus on drug development for aesthetic medicine and chronic inflammation.</p>
<div class="lb-trans"><p><strong>运营：</strong> Caliway Biopharmaceuticals 有限公司通过专注于美学医学和慢性炎症的药物开发产生收入。</p>
</div><p><strong>Insider Ownership:</strong> 24.2%</p>
<div class="lb-trans"><p><strong>内部持股：</strong> 24.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 93.8% p.a.</p>
<div class="lb-trans"><p><strong>盈利增长预测：</strong> 每年 93.8%。</p>
</div><p>Caliway Biopharmaceuticals is experiencing significant growth potential, with revenue forecasted to grow at 89% annually, outpacing the Taiwanese market. The company recently gained recognition by being added to the MSCI Global Standard Index and has initiated pivotal Phase 3 trials for its innovative drug CBL-514. Despite a volatile share price and current lack of meaningful revenue, Caliway's strategic advancements in clinical development position it well for future profitability within three years.</p>
<div class="lb-trans"><p>Caliway Biopharmaceuticals 正经历显著的增长潜力，预计收入每年增长 89%，超过台湾市场。该公司最近因被纳入 MSCI 全球标准指数而获得认可，并已启动其创新药物 CBL-514 的关键三期试验。尽管股价波动较大且当前缺乏有意义的收入，Caliway 在临床开发中的战略进展使其在未来三年内实现盈利的前景良好。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of Caliway Biopharmaceuticals.</li>
<li>The valuation report we've compiled suggests that Caliway Biopharmaceuticals' current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Caliway Biopharmaceuticals 的完整分析未来增长报告。</li>
<li>我们编制的估值报告表明 Caliway Biopharmaceuticals 当前的价格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/f979039c-4fc0-497e-ae4c-0aa7995faeba/chart/earnings-and-revenue-growth"/></p>
<p>TWSE:6919 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>TWSE:6919 截至 2025 年 8 月的盈利和收入增长</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><ul>
<li>Get an in-depth perspective on all 593 Fast Growing Asian Companies With High Insider Ownership by using our screener here.</li>
<li>Curious About Other Options? Trump has pledged to &#34;unleash&#34; American oil and gas and these 22 US stocks have developments that are poised to benefit.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过使用我们的筛选器，深入了解所有 593 家快速增长的亚洲内部持股高的公司。</li>
<li>对其他选项感到好奇？特朗普承诺将&#34;释放&#34;美国的石油和天然气，这 22 只美国股票的发展有望受益。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具如公司和/或信托实体间接持有的股票。所有引用的预测收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

亚洲成长股，内部持股预计收益增长可达 93%